News
Advancing Understanding of Multiple Endocrine Neoplasia (MEN): A Q&A With John Metzcar
We recently spoke with John Metzcar, PhD, president of AMEND USA, neuroendocrine cancer patient and bioinformatics researcher. Can you share a little bit about yourself
Tracing the Roots of Small-Intestinal NETs
By Anna Greene, PhD, Chief Scientific Officer, Neuroendocrine Tumor Research Foundation At NETRF, we often talk about the importance of funding foundational science. These studies
NETRF Clinical Trials Roundup, July 2026: New CAR T-Cell, Radiopharmaceutical, and DLL3-Targeted Approaches in NETs and NECs
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Clinical trial news in neuroendocrine cancer is moving quickly. In this roundup, we highlight recent developments
If Neuroendocrine Cancer Has Spread, Why Would Surgery Still Be Considered?
By Anna C. Greene, PhD, NETRF Chief Scientific Officer When someone is diagnosed with metastatic neuroendocrine cancer, one of the most confusing questions can be:
You Ask, NETRF Answers: Is Neuroendocrine Carcinoma Different From a Neuroendocrine Tumor?
By Anna C. Greene, PhD, NETRF Chief Scientific Officer Patients often hear similar-sounding terms: neuroendocrine tumor, neuroendocrine carcinoma, NET, NEC, high-grade, poorly differentiated, well-differentiated. It
Updates to NETRF’s Board of Scientific Advisors
NETRF BOSA Leadership Transition The Neuroendocrine Tumor Research Foundation is pleased to share updates on the leadership and membership of its Board of Scientific Advisors
Thrivership: Moving Beyond Survival to a Life of Purpose, Connection, and Growth
By Jessica Thomas, LCSW Director of Patient Education, NETRF For many people living with neuroendocrine cancer, the journey begins with a singular focus: survival. A
What Small Cell Lung Cancer Research Can Teach Us About Neuroendocrine Cancer
By Anna C. Greene, PhD | NETRF Chief Scientific Officer In May, I attended the 2026 Small Cell Lung Cancer Consortium hosted by the National
You Ask, NETRF Answers: What Happens After PRRT?
Research-informed answers to your most important questions about neuroendocrine cancer. By Anna C. Greene, PhD, NETRF Chief Scientific Officer You asked. We’re answering. Through the
Grewal Research Update: Neuroendocrine Cancer Research at ASCO 2026
By Udhayvir Singh Grewal, MD GI/Neuroendocrine Medical Oncologist and Assistant Professor of Medical Oncology, Winship Cancer Institute of Emory University School of Medicine Dr. Grewal contributed